Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse - A model mimicking inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 8, Issue 2, 2014, Pages 147-160

  Holgersen, Kristine ^a   Kvist, Peter Helding ^a   Markholst, Helle ^a   Hansen, Axel Kornerup ^b   Holm, Thomas Lindebo ^a  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Crohn's disease; Inflammatory bowel disease; Interleukin 10 knock out mouse; Piroxicam

Indexed keywords

AMPICILLIN; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 23P40; PIROXICAM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; ENTEROCOLITIS; EXPERIMENTAL INFLAMMATORY BOWEL DISEASE; FEMALE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

COX; CROHN'S DISEASE; CYCLOOXYGENASE; IL-10 K.O; INFLAMMATORY BOWEL DISEASE; INTERLEUKIN-10 KNOCK OUT; INTERLEUKIN-10 KNOCK OUT MOUSE; MAB; MEICS; MONOCLONAL ANTIBODY; MURINE ENDOSCOPIC INDEX OF COLITIS SEVERITY; NON-STEROIDAL ANTI-INFLAMMATORY DRUG; NSAID; PAC; PIROXICAM; PIROXICAM-ACCELERATED COLITIS; WILD TYPE; WT;

AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; COLON; CYTOKINES; DIARRHEA; DISEASE MODELS, ANIMAL; ENTEROCOLITIS; FEMALE; GRANULOMA; HYPERPLASIA; ILEUM; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTESTINAL MUCOSA; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; NEUTROPHILS; PIROXICAM; WEIGHT LOSS;

EID: 84892838555     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.08.002     Document Type: Article

References (57)

1. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
2. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24:2-6.
3. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet 2012, 380:1590-1605.
4. Ordas I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J. Ulcerative colitis. Lancet 2012, 380:1606-1619.
5. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu Rev Immunol 2010, 28:573-621.
6. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006, 3:390-407.
7. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010, 105:289-297.
8. Wirtz S., Neurath M.F. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007, 59:1073-1083.
9. Koboziev I., Karlsson F., Zhang S., Grisham M.B. Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies. Inflamm Bowel Dis 2011, 17:1229-1245.
10. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
11. Moore K.W., de Waal M.R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
12. Paul G., Khare V., Gasche C. Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest 2012, 42:95-109.
13. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147:3815-3822.
14. Tagore A., Gonsalkorale W.M., Pravica V., Hajeer A.H., McMahon R., Whorwell P.J., et al. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 1999, 54:386-390.
15. Begue B., Verdier J., Rieux-Laucat F., Goulet O., Morali A., Canioni D., et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol 2011, 106:1544-1555.
16. Glocker E.O., Kotlarz D., Boztug K., Gertz E.M., Schaffer A.A., Noyan F., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009, 361:2033-2045.
17. Berg D.J., Davidson N., Kuhn R., Muller W., Menon S., Holland G., et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996, 98:1010-1020.
18. Madsen K.L., Malfair D., Gray D., Doyle J.S., Jewell L.D., Fedorak R.N. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 1999, 5:262-270.
19. Sellon R.K., Tonkonogy S., Schultz M., Dieleman L.A., Grenther W., Balish E., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998, 66:5224-5231.
20. Chichlowski M., Westwood G.S., Abraham S.N., Hale L.P. Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLoS One 2010, 5:e12220.
21. Berg D.J., Zhang J., Weinstock J.V., Ismail H.F., Earle K.A., Alila H., et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 2002, 123:1527-1542.
22. Smith W.L., DeWitt D.L. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996, 62:167-215.
23. Hale L.P., Gottfried M.R., Swidsinski A. Piroxicam treatment of IL-10-deficient mice enhances colonic epithelial apoptosis and mucosal exposure to intestinal bacteria. Inflamm Bowel Dis 2005, 11:1060-1069.
24. Bjarnason I., Hayllar J., MacPherson A.J., Russell A.S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993, 104:1832-1847.
25. Kaufmann H.J., Taubin H.L. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987, 107:513-516.
26. van der Staay F.J., Arndt S.S., Nordquist R.E. Evaluation of animal models of neurobehavioral disorders. Behav Brain Funct 2009, 5:11.
27. Nicklas W., Baneux P., Boot R., Decelle T., Deeny A.A., Fumanelli M., et al. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 2002, 36:20-42.
28. Murthy S.N.S., Cooper H.S., Shim H., Shah R.S., Ibrahim S.A., Sedergran D.J. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 1993, 38:1722-1734.
29. Bleich A., Mahler M., Most C., Leiter E.H., Liebler-Tenorio E., Elson C.O., et al. Refined histopathologic scoring system improves power to detect colitis QTL in mice. Mamm Genome 2004, 15:865-871.
30. Becker C., Fantini M.C., Neurath M.F. High resolution colonoscopy in live mice. Nat Protoc 2007, 1:2900-2904.
31. Henriksen M., Jahnsen J., Lygren I., Stray N., Sauar J., Vatn M.H., et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008, 57:1518-1523.
32. Kapsoritakis A.N., Koukourakis M.I., Sfiridaki A., Potamianos S.P., Kosmadaki M.G., Koutroubakis I.E., et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001, 96:776-781.
33. Chiorean M.V., Sandrasegaran K., Saxena R., Maglinte D.D., Nakeeb A., Johnson C.S. Correlation of CT enteroclysis with surgical pathology in Crohn's disease. Am J Gastroenterol 2007, 102:2541-2550.
34. Maiden L., Thjodleifsson B., Theodors A., Gonzalez J., Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128:1172-1178.
35. Maiden L., Thjodleifsson B., Seigal A., Bjarnason I.I., Scott D., Birgisson S., et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007, 5:1040-1045.
36. Sigthorsson G., Simpson R.J., Walley M., Anthony A., Foster R., Hotz-Behoftsitz C., et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002, 122:1913-1923.
37. Takeuchi K., Tanaka A., Kato S., Amagase K., Satoh H. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta 2010, 411:459-466.
38. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962.
39. Shih D.Q., Targan S.R. Insights into IBD pathogenesis. Curr Gastroenterol Rep 2009, 11:473-480.
40. Shim J.O., Hwang S., Yang H.R., Moon J.S., Chang J.Y., Ko J.S., Park S.S., Kang G.H., Kim W.S., Seo J.K. Interleukin-10 receptor mutations in children with neonatal-onset Crohn's disease and intractable ulcerating enterocolitis. Eur J Gastroenterol Hepatol 2013.
41. Chichlowski M., Hale L.P. Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad. Am J Physiol Gastrointest Liver Physiol 2008, 295:G1139-G1149.
42. Papadakis K. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep 2004, 4:83-89.
43. Roberts-Thomson I.C., Fon J., Uylaki W., Cummins A.G., Barry S. Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol 2011, 5:703-716.
44. -/- mice results from IL-13Ralpha2-mediated attenuation of IL-13 activity. Gastroenterology 2011, 140:254-264.
45. Fuss I.J., Becker C., Yang Z., Groden C., Hornung R.L., Heller F., et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006, 12:9-15.
46. Langrish C.L., McKenzie B.S., Wilson N.J., De Waal Malefyt R., Kastelein R.A., Cua D.J. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004, 202:96-105.
47. Sandborn W.J., Gasink C., Gao L.L., Blank M.A., Johanns J., Guzzo C., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012, 367:1519-1528.
48. Sandborn W.J., Feagan B.G., Fedorak R.N., Scherl E., Fleisher M.R., Katz S., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
49. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316.
50. Uhlig H.H., McKenzie B.S., Hue S., Thompson C., Joyce-Shaikh B., Stepankova R., et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006, 25:309-318.
51. Kullberg M.C., Jankovic D., Feng C.G., Hue S., Gorelick P.L., McKenzie B.S., et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 2006, 203:2485-2494.
52. O'Farrell A.M., Liu Y., Moore K.W., Mui A.L.F. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J 1998, 17:1006-1018.
53. Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O'Garra A., Murphy K.M. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993, 260:547-549.
54. Macpherson A., Khoo U.Y., Forgacs I., Philpott-Howard J., Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996, 38:365-375.
55. Solomon L., Mansor S., Mallon P., Donnelly E., Hoper M., Loughrey M., et al. The dextran sulphate sodium (DSS) model of colitis: an overview. Comp Clin Pathol 2010, 19:235-239.
56. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98:694-702.
57. Cooper H.S., Murthy S.N., Shah R.S., Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993, 69:238-249.